Page 1 | Search Results | Hematology, ASH Education Program

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Management of older Hodgkin lymphoma patients

Andrew M. Evens, Jordan Carter, Kah Poh Loh, Kevin A. David

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 233–242.

https://doi.org/10.1182/hematology.2019000028

Published: 2019

Journal Articles

How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide

Shannon R. McCurdy, Leo Luznik

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 513–521.

https://doi.org/10.1182/hematology.2019001323

Published: 2019

Journal Articles

Is there a role for immunosuppression in antiphospholipid syndrome?

Ecem Sevim, Rohan Willis, Doruk Erkan

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 426–432.

https://doi.org/10.1182/hematology.2019000073

Published: 2019

Journal Articles

Selecting Frontline Therapy for CLL in 2018

Nitin Jain

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 242–247.

https://doi.org/10.1182/asheducation-2018.1.242

Published: 2018

Journal Articles

The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment

Gianluca Gaidano, Davide Rossi

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 329–337.

https://doi.org/10.1182/asheducation-2017.1.329

Published: 2017

Journal Articles

Sequencing of chronic lymphocytic leukemia therapies

Jacqueline C. Barrientos

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 128–136.

https://doi.org/10.1182/asheducation-2016.1.128

Published: 2016

Journal Articles

Response-adapted frontline therapy for Hodgkin lymphoma: are we there yet?

Peter W. M. Johnson

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 316–322.

https://doi.org/10.1182/asheducation-2016.1.316

Published: 2016

Journal Articles

Walking a tightrope: clinical use of ibrutinib in mantle cell lymphoma in the elderly

Marco Ruella, Pierre Soubeyran

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 432–436.

https://doi.org/10.1182/asheducation-2016.1.432

Published: 2016

Journal Articles

Use of alternative donors for allogeneic stem cell transplantation

Claudio Anasetti

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 220–224.

https://doi.org/10.1182/asheducation-2015.1.220

Published: 2015

Journal Articles

Prognostic markers and standard management of chronic lymphocytic leukemia

Stephan Stilgenbauer

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 368–377.

https://doi.org/10.1182/asheducation-2015.1.368

Published: 2015

Journal Articles

Treatment of thrombotic thrombocytopenic purpura beyond therapeutic plasma exchange

Paul Coppo, Antoine Froissart

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 637–643.

https://doi.org/10.1182/asheducation-2015.1.637

Published: 2015

Journal Articles

Double-hit lymphomas: current paradigms and novel treatment approaches

Kieron Dunleavy

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 107–112.

https://doi.org/10.1182/asheducation-2014.1.107

Published: 2014

Journal Articles

Transplantation for mantle cell lymphoma: is it the right thing to do?

Michael E. Williams

Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 568–574.

https://doi.org/10.1182/asheducation-2013.1.568

Published: 2013

Journal Articles

Treatment strategies for aggressive lymphomas: what works?

Wyndham H. Wilson

Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 584–590.

https://doi.org/10.1182/asheducation-2013.1.584

Published: 2013

Journal Articles

Therapeutic challenges in acquired factor VIII deficiency

Peter W. Collins

Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 369–374.

https://doi.org/10.1182/asheducation.V2012.1.369.3798356

Published: 2012

Journal Articles

Using the Biology of Chronic Lymphocytic Leukemia to Choose Treatment

Peter Hillmen

Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 104–109.

https://doi.org/10.1182/asheducation-2011.1.104

Published: 2011

Journal Articles

What is the Benefit of Maintenance Therapy with Lenalidomide or Bortezomib after Autologous Stem Cell Transplantation in Multiple Myeloma and What is the Risk of Developing a Secondary Primary Malignancy?

Emma Scott, Donna Reece

Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 205–207.

https://doi.org/10.1182/asheducation-2011.1.205

Published: 2011

Journal Articles

Understanding and Managing Ultra High-Risk Chronic Lymphocytic Leukemia

Stephan Stilgenbauer, Thorsten Zenz

Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 481–488.

https://doi.org/10.1182/asheducation-2010.1.481

Published: 2010

Journal Articles

The Past: What We Have Learned in the Last Decade

Peter Borchmann, Andreas Engert

Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 101–107.

https://doi.org/10.1182/asheducation-2010.1.101

Published: 2010

Journal Articles

Aplastic Anemia: First-line Treatment by Immunosuppression and Sibling Marrow Transplantation

Jakob R. Passweg, Judith C.W. Marsh

Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 36–42.

https://doi.org/10.1182/asheducation-2010.1.36

Published: 2010

NARROW

Management of older Hodgkin lymphoma patients

How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide

Is there a role for immunosuppression in antiphospholipid syndrome?

Selecting Frontline Therapy for CLL in 2018

The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment

Sequencing of chronic lymphocytic leukemia therapies

Response-adapted frontline therapy for Hodgkin lymphoma: are we there yet?

Walking a tightrope: clinical use of ibrutinib in mantle cell lymphoma in the elderly

Use of alternative donors for allogeneic stem cell transplantation

Prognostic markers and standard management of chronic lymphocytic leukemia

Treatment of thrombotic thrombocytopenic purpura beyond therapeutic plasma exchange

Double-hit lymphomas: current paradigms and novel treatment approaches

Transplantation for mantle cell lymphoma: is it the right thing to do?

Treatment strategies for aggressive lymphomas: what works?

Therapeutic challenges in acquired factor VIII deficiency

Using the Biology of Chronic Lymphocytic Leukemia to Choose Treatment

What is the Benefit of Maintenance Therapy with Lenalidomide or Bortezomib after Autologous Stem Cell Transplantation in Multiple Myeloma and What is the Risk of Developing a Secondary Primary Malignancy?

Understanding and Managing Ultra High-Risk Chronic Lymphocytic Leukemia

The Past: What We Have Learned in the Last Decade

Aplastic Anemia: First-line Treatment by Immunosuppression and Sibling Marrow Transplantation

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only